Effects of antipsychotic medication on muscarinic M1 receptor mRNA expression in the rat brain

Journal of Neuroscience Research

Volumn 86, Issue 2, 2008, Pages 457-464

  Han, Mei ^a,b   Newell, Kelly ^a,b   Zavitsanou, Katerina ^a,b,c   Deng, Chao ^a,b   Huang, Xu Feng ^a,b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^c AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

Author keywords

Aripirazole; Hippocampus; mRNA expression; Muscarinic M1 receptor; Olanzapine; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; MESSENGER RNA; MUSCARINIC M1 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BRAIN REGION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HIPPOCAMPUS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR AFFINITY; STATISTICAL SIGNIFICANCE; SUBSTANTIA NIGRA; TREATMENT DURATION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRAIN; FEMALE; HALOPERIDOL; IN SITU HYBRIDIZATION; PIPERAZINES; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MUSCARINIC M1; RNA, MESSENGER; TIME;

EID: 38849101763     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21491     Document Type: Article

References (34)

1. Bernard V, Normand E, Bloch B. 1992. Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes. J Neurosci 12:3591-3600.
2. Bubser M, Deutch AY. 2002. Differential effects of typical and atypical antipsychotic drugs on striosome and matrix compartments of the striatum. Eur J Neurosci 15:713-720.
3. Bymaster FP, Felder CC, Tzavara E, Nomikos GG, Calligaro DO, McKinzie DL. 2003a. Muscarinic mechanisms of antipsychotic atypicality. Prog Neuropsychoph 27:1125-1143.
4. Bymaster FP, McKinzie DL, Felder CC, Wess J. 2003b. Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem Res 28:437-442.
5. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. 2000. Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 48:381-388.
6. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. 2001. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 158:918-925.
7. Dean B, Crook JM, Opeskin K, Hill C, Keks N, Copolov DL. 1996. The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry 1:54-58.
8. Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E. 2002. Decreased muscarinicl receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 7:1083-1091.
9. Dean B, Gray L, Keriakous D, Scarr E. 2004. A comparison of M1 and M4 muscarinic receptors in the thalamus from control subjects and subjects with schizophrenia. Thalamus Rel Syst 2:287-295.
10. DeLeon A, Patel NC, Lynn Crismon M. 2004. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26:649-666.
11. Deng C, Huang XF. 2005. Decreased density of muscarinic receptors in the superior temporal gyrusin schizophrenia. J Neurosci Res 81:883-890.
12. Erzin-Waten C, Muller P, Seeman P. 1976. Catalepsy induced by morphine or haloperidol: effects of apomorphine and anticholinergic drugs. Can J Physiol Pharmacol 54:516-519.
13. Fadel J, Bubser M, Deutch AY. 2002. Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J Neurosci 22:6742-6746.
14. Felder CC, Porter AC, Skillman TL, Zhang L, Bymaster FP, Nathanson NM, Hamilton SE, Gomeza J, Wess J, McKinzie DL. 2001. Elucidating the role of muscarinic receptors in psychosis. Life Sci 68:2605-2613.
15. Gerber DJ, Sotnikova TD, Gainetdinov RR, Huang SY, Caron MG, Tonegawa S. 2001. Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci U S A 98:15312-15317.
16. Gomeza J, Zhang L, Kostenis E, Felder C, Bymaster F, Brodkin J, Shannon H, Xia B, Deng C, Wess J. 1999. Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M(4) muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci U S A 96:10483-10488.
17. Han M, Deng C, Tan Y, Huang X. 2006. Aripiprazole treatment increases D2 receptor mRNA expression in the ventral tegmental area of rat brain. Proc Australian Neurosci Soc 26:105.
18. Huang X, Han M, Storlien LH. 2004. Differential expression of 5-HT(2A) and 5-HT(2C) receptor mRNAs in mice prone, or resistant, to chronic high-fat diet-induced obesity. Brain Res Mol Brain Res 127:39-47.
19. Huang X-F, Han M, Huang X, Zavitsanou K, Deng C. 2006. Olanzapine differentially affects 5-HT2A and 2C receptor mRNA expression in the rat brain. Behav Brain Res 171:355-362.
20. Huang-Brown KM, Guhad FA. 2002. Chocolate, an effective means of oral drug delivery in rats [see comment]. Lab Animal 31:34-36.
21. Kapur S, Wadenberg ML, Remington G. 2000. Are animal studies of antipsychotics appropriately dosed? Lessons from the bedside to the bench [see comment]. Can J Psychiat 45:241-246.
22. Kapur S, VanderSpek SC, Brownlee BA, Nobrega JN. 2003. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical condition: a suggested solution based on in vivo occupancy. J Pharmacol Exp Ther 305:625-631.
23. Mancama D, Arranz MJ, Landau S, Kerwin R. 2003. Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 119:2-6.
24. McClintock MK. 1978. Estrous synchrony and its mediation by airborne chemical communication (Rattus norvegicus). Horm Behav 10:264-276.
25. Newell KA, Zavitsanou K, Kum Jew S, Huang XF. 2007a. Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Prog Neuropsychoph 31:225-233.
26. Newell KA, Zavitsanou K, Huang XF. 2007b. Opposing short- and long-term effects on muscarinic M1/4 receptor binding following chronic phencyclidine treatment. J Neurosci Res 85:1358-1363.
27. Paxinos G, Watson C. 1997. The rat brain in stereotaxic coordinates, 3rd ed. San Diego: Academic Press.
28. Remington G, Kapur S. 2000. Atypical antipsychotics: are some more atypical than others [see comment]? Psychopharmacology 148:3-15.
29. Schank JC. 2001. Do Norway rats (Rattus norvegicus) synchronize their estrous cycles? Physiol Behav 72:129-139.
30. Vizi ES, Kiss JP. 1998. Neurochemistry and pharmacology of the major hippocampal transmitter systems: synaptic and nonsynaptic interactions [see comment]. Hippocampus 8:566-607.
31. Wess J, Duttaroy A, Zhang W, Gomeza J, Cui Y, Miyakawa T, Bymaster FP, McKinzie L, Felder CC, Lamping KG, Faraci FM, Deng C, Yamada M. 2003. M1-M5 muscarinic receptor knockout mice as novel tools to study the physiological roles of the muscarinic cholinergic system. Recept Chan 9:279-290.
32. Zar J. 1999. Biostatiscal Analysis. New Jersey: Prentice Hall.
33. Zavitsanou K, Katsifis A, Mattner F, Huang XF. 2004. Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 29:619-625.
34. Zavitsanou K, Nguyen VH, Han M, Huang XF. 2007. Effects of typical and atypical antipsychotic drugs on rat brain muscarinic receptors. Neurochem Res 32:525-532.